A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma

Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells

(2020) Maria V. Yusenko et al.   CANCER LETTERS

Common variants in signaling transcription-factor-binding sites drive phenotypic variability in red blood cell traits

(2020) Avik Choudhuri et al.   NATURE GENETICS

Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma

(2019) Vatche Tchekmedyian et al.   JOURNAL OF CLINICAL ONCOLOGY

ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notchact mut).

(2019) Renata Ferrarotto et al.   JOURNAL OF CLINICAL ONCOLOGY

IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors

(2019) Andersson et al.   Cells

MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma

(2019) Yue Jiang et al.   ORAL ONCOLOGY

N-Terminal Truncated Myb with New Transcriptional Activity Produced Through Use of an Alternative MYB Promoter in Salivary Gland Adenoid Cystic Carcinoma

(2019) Candace A. Frerich et al.   Cancers

Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma

(2018) Joseph Mandelbaum et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

(2017) Renata Ferrarotto et al.   JOURNAL OF CLINICAL ONCOLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

(2017) Priscila H. Goncalves et al.   Oncotarget

A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma

(2016) A. L. Ho et al.   ANNALS OF ONCOLOGY

An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma

(2016) Yotam Drier et al.   NATURE GENETICS

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize

(2016) Stephen R. Adams et al.   Nature Communications

Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma

(2016) Arya Amini et al.   JAMA Otolaryngology-Head & Neck Surgery

Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations

(2015) Y. Mitani et al.   CLINICAL CANCER RESEARCH

Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma

(2015) K. J. Brayer et al.   Cancer Discovery

Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck

(2013) David J. Thomson et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma

(2013) M. Gao et al.   INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

(2013) Francesco Lo-Coco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinically significant copy number alterations and complex rearrangements ofMYBandNFIBin head and neck adenoid cystic carcinoma

(2012) Marta Persson et al.   GENES CHROMOSOMES & CANCER

A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC

(2011) N. G. Chau et al.   ANNALS OF ONCOLOGY

The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma

(2011) A Fehr et al.   JOURNAL OF PATHOLOGY

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

(2010) F. Lo-Coco et al.   BLOOD

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

(2010) B. L. Powell et al.   BLOOD

Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance

(2010) Y. Mitani et al.   CLINICAL CANCER RESEARCH

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review

(2010) Scott A Laurie et al.   LANCET ONCOLOGY

Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck

(2009) M. Persson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER